Australia markets open in 1 hour 17 minutes

Ironwood Pharmaceuticals, Inc. (IRWD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
12.61-0.06 (-0.47%)
At close: 4:00PM EDT
12.61 0.00 (0.00%)
After hours: 04:02PM EDT

Ironwood Pharmaceuticals, Inc.

100 Summer Street
Suite 2300
Boston, MA 02110
United States
617 621 7722
http://www.ironwoodpharma.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees232

Key executives

NameTitlePayExercisedYear born
Ms. Julie H. McHughExec. Chairman95kN/A1964
Mr. Thomas A. McCourtCEO & Director944.57k284.33k1957
Mr. Jason RickardCOO & Sr. VP of Operations940.06kN/A1971
Dr. Michael Shetzline M.D., Ph.D.Chief Medical Officer, Sr. VP and Head of R&D770.28kN/A1959
Mr. Brian M. CaliCo-Founder and Sr. VP of R&D Strategy & External InnovationN/AN/AN/A
Mr. G. Todd MilneCo-Founder and VP of sGC R&DN/AN/AN/A
Mr. Ronald SilverCorp. Controller & Principal Accounting OfficerN/AN/A1982
Mr. John MinardoSr. VP & Chief Legal OfficerN/AN/AN/A
Mr. Jonathan RosinSr. VP of HRN/AN/AN/A
Dr. Christopher I. WrightChief Devel. Officer & Sr. VP of Global Devel.N/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Corporate governance

Ironwood Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 July 2021 is 3. The pillar scores are Audit: 3; Board: 1; Shareholder rights: 6; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.